Jacob Kimmel
Jacob C. Kimmel is the co-founder and president of NewLimit, a biotechnology company focused on developing reprogramming medicines for aging. Their approach involves restoring youthful function in old cells by reprogramming the epigenome, with the goal of treating intractable diseases and extending healthspan. The company leverages artificial intelligence systems and functional genomics to achieve this. Previously, Jacob led research programs at Calico, focusing on repurposing developmental programs to restore youthful gene expression in aging cells and investigating how aging manifests differently across cell types. His earlier work at UCSF involved developing methods to infer cell state changes from timelapse imaging data and studying age-related changes in muscle stem cells.
Jacob Kimmel
Jacob C. Kimmel is the co-founder and president of NewLimit, a biotechnology company focused on developing reprogramming medicines for aging. Their approach involves restoring youthful function in old cells by reprogramming the epigenome, with the goal of treating intractable diseases and extending healthspan. The company leverages artificial intelligence systems and functional genomics to achieve this. Previously, Jacob led research programs at Calico, focusing on repurposing developmental programs to restore youthful gene expression in aging cells and investigating how aging manifests differently across cell types. His earlier work at UCSF involved developing methods to infer cell state changes from timelapse imaging data and studying age-related changes in muscle stem cells.